Sei Investments Co. Purchases 1,245 Shares of PRA Health Sciences, Inc. (PRAH)

Sei Investments Co. boosted its position in PRA Health Sciences, Inc. (NASDAQ:PRAH) by 8.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,899 shares of the medical research company’s stock after acquiring an additional 1,245 shares during the period. Sei Investments Co.’s holdings in PRA Health Sciences were worth $1,212,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of PRAH. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock valued at $112,000 after acquiring an additional 160 shares during the last quarter. Carroll Financial Associates Inc. lifted its stake in PRA Health Sciences by 127.4% in the third quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock valued at $112,000 after buying an additional 790 shares during the period. Trustmark National Bank Trust Department acquired a new position in PRA Health Sciences in the second quarter valued at about $225,000. Aperio Group LLC acquired a new position in PRA Health Sciences in the second quarter valued at about $233,000. Finally, Jennison Associates LLC acquired a new position in PRA Health Sciences in the third quarter valued at about $252,000. Institutional investors and hedge funds own 98.49% of the company’s stock.

PRAH has been the topic of several analyst reports. Jefferies Group reissued a “buy” rating and issued a $92.00 target price (up previously from $88.00) on shares of PRA Health Sciences in a research note on Thursday, August 10th. Citigroup reissued a “buy” rating and issued a $93.00 target price (up previously from $90.00) on shares of PRA Health Sciences in a research note on Thursday, August 10th. Zacks Investment Research raised PRA Health Sciences from a “hold” rating to a “buy” rating and set a $83.00 target price on the stock in a research note on Tuesday, August 15th. Mizuho initiated coverage on PRA Health Sciences in a research note on Thursday, September 21st. They issued a “buy” rating and a $82.00 target price on the stock. Finally, Robert W. Baird reissued a “buy” rating and issued a $88.00 target price on shares of PRA Health Sciences in a research note on Monday, October 9th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. PRA Health Sciences presently has an average rating of “Buy” and an average target price of $89.09.

Shares of PRA Health Sciences, Inc. (NASDAQ:PRAH) opened at $81.60 on Friday. The company has a market capitalization of $5,132.95, a PE ratio of 29.78, a PEG ratio of 1.40 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 1.01 and a debt-to-equity ratio of 1.38. PRA Health Sciences, Inc. has a 1 year low of $53.41 and a 1 year high of $84.38.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $0.88 EPS for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.03. The company had revenue of $494.55 million for the quarter, compared to analyst estimates of $477.89 million. PRA Health Sciences had a return on equity of 21.66% and a net margin of 5.64%. PRA Health Sciences’s revenue was up 23.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.64 earnings per share. research analysts forecast that PRA Health Sciences, Inc. will post 3.2 EPS for the current year.

In other news, Director Matthew P. Young sold 5,115 shares of the firm’s stock in a transaction dated Thursday, November 16th. The stock was sold at an average price of $79.90, for a total transaction of $408,688.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/08/sei-investments-co-purchases-1245-shares-of-pra-health-sciences-inc-prah.html.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply